AOP Orphan strengthens core CNS specialty business with high promise in movement disorder treatments
Posted: 19 June 2015 |
AOP Orphan Pharmaceuticals AG has announced the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member state…
AOP Orphan Pharmaceuticals AG announced today the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member state.
Tardive dyskinesia (TD) is a chronic movement disorder caused by prolonged exposure to medications that block dopamine receptors, including antipsychotic drugs and some drugs used to treat nausea. It is characterized by involuntary, repetitive movements that usually involve the face and in more severe cases affect the trunk and/or extremities. Involuntary movements of the lips, cheeks, tongue and jaw are typical. The disorder is irreversible in the majority of cases.
“The opportunity to bring relief to the many patients who face the debilitating effects of movement disorders and suffer from the effects of conditions such as tardive dyskinesia is greatly needed and humbling,” said Dr. Rudolf Widmann, CEO and founder of AOP Orphan.
“Within AOP Orphan, we have a rich history in building relationships with patients and physicians to match treatments to those affected with CNS disorders,” said Georg Fischer, MD, Board Member and Business Development Director at AOP Orphan. “People living with movement disorders and those around them often need support and services beyond medication. We have the infrastructure, existing strong relationships with neurologists, therapeutic expertise in CNS and passion in place to assist them.”